clinical trial · NCT05448170
Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)
GlaxoSmithKline·—·available
PruritusLinerixibat
brief summary
The goal of this compassionate use program is to provide a mechanism to supply linerixibat, on an individual named patient basis. This program is for treatment of individuals who have cholestatic pruritus associated with PBC who are deemed at high risk of a significant clinical event as a result of their pruritus and for whom all available pharmaceutical treatment options for cholestatic pruritus have been unsuccessful or are considered to not be appropriate.
started
—
primary completion
—
completion
—
last updated
Feb 27, 2025
official title
Linerixibat Compassionate Use for Cholestatic Pruritus in Adult Patients With Primary Biliary Cholangitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol